Fangke Health, Novo Nordisk Partner to Revolutionize Chronic Disease Management

On July 18, during the third China International Supply Chain Promotion Expo, Fangke Health, a leading AI and internet-based healthcare company, signed a memorandum of understanding with Novo Nordisk, a global biopharmaceutical leader. The collaboration aims to enhance the management of severe chronic diseases such as diabetes and obesity by integrating Novo Nordisk's expertise in treatment and innovation with Fangke Health's advanced digital health management solutions.

Dr. Xie Fangmin, the founder, chairman, and CEO of Fangke Health, and Dr. Zhou Xiaoping, the global senior vice president and president of Greater China at Novo Nordisk, attended the signing ceremony. The partnership will focus on creating a comprehensive health management service loop that includes medication guidance, reminders, effect tracking, and health education. This initiative aims to shift the focus from disease treatment to health promotion, providing patients with a more convenient and high-quality one-stop service.

Dr. Xie Fangmin expressed his enthusiasm for the collaboration, stating, "We hope to work with Novo Nordisk, a global leader in biopharmaceuticals, to explore the application of AI technology. By addressing the pain points in traditional health management models, we aim to provide innovative digital solutions for global sugar management and weight management."

Dr. Zhou Xiaoping echoed this sentiment, highlighting Novo Nordisk's century-long commitment to driving change and combating severe chronic diseases. She noted that the collaboration will integrate scientific prevention and treatment of chronic diseases with digital innovation, enhancing awareness and early detection, diagnosis, and treatment of diabetes and obesity within a smart healthcare framework.

Looking ahead, the partnership is poised to explore further innovations in the digital transformation of the medical industry. This collaboration is expected to benefit a broader range of patients with severe chronic diseases and contribute to the accelerated realization of the "Healthy China 2030" strategic goals. By leveraging the strengths of both companies, the initiative aims to set a new benchmark for the digital management of chronic diseases, providing patients with more personalized and efficient healthcare services.